Labiotech.eu

gene therapy osteoarthritis genequine2 1

News and Trends 14 Dec 2017

German Biotech’s Gene Therapy for Osteoarthritis Plucked by US Pharma

GeneQuine’s gene therapy for osteoarthritis in the knee has been acquired by US pharma company Flexion Therapeutics for up to $64M. GeneQuine is developing a gene therapy for the treatment of osteoarthritis. It uses helper-dependent adenoviruses, which provide long-term expression, a higher packaging capacity, reduced immunogenicity and they do not integrate into the host genome. It seems like yesterday […]

December 14, 2017 - 3 minutesmins - By Alex Dale

News and Trends 14 Dec 2017

Belgian Biotech Raises $231M to Continue Developing its Antibody Therapies

Argenx has smashed its target of $150M for its US offering, which will support its cancer and autoimmune disease antibodies through the clinic. Argenx develops antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Today, the Belgian biotech has announced that it has raised a very impressive $231M (€195M) following positive results at ASH. The company […]

December 14, 2017 - 1 minutemin - By Alex Dale

Best in Biotech 14 Dec 2017

10 Biotechnology Books To Read These Winter Holidays

Here is a list of some of the best biotechnology books to add to your 2018 to-read list and get up to date with the ins and outs of the biotech world. Winter is here, at least for those of us living in the Northern hemisphere. I am personally looking forward to warm evenings at […]

December 14, 2017 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Dec 2017

Biotech and Pharma Giants Make a Good Start to Phase II Trial for Skin Cancer

Regeneron and Sanofi have announced positive early results from a Phase II study investigating their skin cancer antibody, cemiplimab. Despite deciding to end their antibody partnership at the end of the year, Regeneron and Sanofi are still committed to pushing through a number of candidates. One of these, cemiplimab, is a programmed cell death protein-1 (PD-1) checkpoint […]

December 13, 2017 - 3 minutesmins - By Alex Dale

News and Trends 13 Dec 2017

Off-the-Shelf CAR-T Cells Struggle to Improve Cancer Treatment

Data presented at ASH 2017 shows that Servier and Pfizer’s UCART19, an allogeneic CAR-T therapy originally developed by Cellectis, might struggle to outperform autologous CAR-T cells. CAR-T cell therapy has proved to be effective at treating cancer in patients for whom scarce hope was left. Yet pricing is still a big concern. Companies like Cellectis are trying […]

December 13, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

CRISPR Therapeutics clinical trials CRISPR Cas9

News and Trends 13 Dec 2017

CRISPR Therapeutics Plans First CRISPR/Cas9 Clinical Trial in Europe for 2018

CRISPR Therapeutics and Vertex Pharmaceuticals are taking action to start a first clinical trial with CRISPR/Cas9 in Europe in 2018. The blood disorder β-thalassemia could soon be the first human disease to be treated using CRISPR/Cas9 technology in Europe. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have announced the first candidate from their collaboration that will go […]

December 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

antibiotics resistance peptides Aelin3 Edited

News and Trends 13 Dec 2017

New Belgian Biotech Secures €27M Series A to Develop Peptide Antibiotics

Aelin Therapeutics will develop its Pept-in technology, which could hold the answer to the growing antibiotics resistance crisis. Aelin Therapeutics is a Belgian biotherapeutics company that is hoping to pioneer Pept-in, protein knockdown drugs that could revolutionize the antibiotics field and open up previously undruggable targets. The company was founded by VIB and partner universities […]

December 13, 2017 - 3 minutesmins - By Alex Dale

In Depth 13 Dec 2017

How Biotech Could Change Your Christmas Dinner

Turkey, roast potatoes, gravy, pigs in blankets… For me, food is an essential part of Christmas. But, biotechs are working on approaches that in the next few years could change the food that we’re scarfing down. With the big day not far away, many of our minds will have crept ahead to Christmas dinner. On […]

December 13, 2017 - 6 minutesmins - By Alex Dale

News and Trends 12 Dec 2017

British Biotech Gets $15M as its Armed Oncolytic Virus Enters the Clinic

PsiOxus will receive a generous milestone payment from Bristol-Myers Squibb, which licenses the biotech’s oncolytic virus technology. PsiOxus hopes to become the world’s leading immuno-oncolytic company, systemically administering “gene therapy for tumors.” Today, the biotech has announced that its Clinical Trial Application for NG-348 for the treatment of solid tumors, has been approved. Under the terms of […]

December 12, 2017 - 2 minutesmins - By Alex Dale

News and Trends 12 Dec 2017

Immunotherapy for Uveal Melanoma is on Track for Early Access in the UK

The UK grants Immunocore access to a fast-track scheme that will make its immunotherapy IMCgp100 available to patients with uveal melanoma before approval. The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has deemed Immunocore’s technology worth being used by patients before it’s approved. The regulatory agency has granted Promising Innovative Medicines (PIM) designation to IMCgp100 for […]

December 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Dec 2017

New Dutch Biotech Sails Straight into Phase II with €25M Series A to Treat NASH

NorthSea Therapeutics has been founded in the Netherlands to develop a drug against NASH, a disease with no treatment and a huge market. With a €25M investment in Series A, NorthSea Therapeutics is all set to start Phase II trials in nonalcoholic steatohepatitis (NASH) and take on a very profitable market. The fundraising was led by Forbion […]

December 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Dec 2017

An FDA First! Sanofi’s “Follow-on” Insulin Gets a Thumbs Up

Sanofi’s rapid-action insulin, Admelog, will be the first “follow-on” insulin product on the market to help diabetics manage their blood sugar at mealtimes. Sanofi has announced the FDA approval of Admelog, the first “follow-on” mealtime insulin available to type 1 and type 2 diabetics. This gave the company’s stock price a boost of 1.1% this morning, which is […]

December 12, 2017 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

German Biotech’s Gene Therapy for Osteoarthritis Plucked by US Pharma

Belgian Biotech Raises $231M to Continue Developing its Antibody Therapies

10 Biotechnology Books To Read These Winter Holidays

Biotech and Pharma Giants Make a Good Start to Phase II Trial for Skin Cancer

Off-the-Shelf CAR-T Cells Struggle to Improve Cancer Treatment

CRISPR Therapeutics Plans First CRISPR/Cas9 Clinical Trial in Europe for 2018

New Belgian Biotech Secures €27M Series A to Develop Peptide Antibiotics

How Biotech Could Change Your Christmas Dinner

British Biotech Gets $15M as its Armed Oncolytic Virus Enters the Clinic

Immunotherapy for Uveal Melanoma is on Track for Early Access in the UK

New Dutch Biotech Sails Straight into Phase II with €25M Series A to Treat NASH

An FDA First! Sanofi’s “Follow-on” Insulin Gets a Thumbs Up

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!